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Abstract
Background & Aims: Molecular mechanisms by which hypoxia might contribute to hepa-
tosteatosis, the earliest stage in non-alcoholic fatty liver disease (NAFLD) pathogenesis, 
remain still to be elucidated. We aimed to assess the impact of hypoxia-inducible factor 
2α (HIF2α) on the fatty acid translocase CD36 expression and function in vivo and in vitro.
Methods: CD36 expression and intracellular lipid content were determined in hypoxic 
hepatocytes, and in hypoxic CD36- or HIF2α -silenced human liver cells. Histological 
analysis, and HIF2α and CD36 expression were evaluated in livers from animals in 
which von Hippel-Lindau (Vhl) gene is inactivated (Vhlf/f-deficient mice), or both Vhl 
and Hif2a are simultaneously inactivated (Vhlf/fHif2α/f-deficient mice), and from 33 
biopsy-proven NAFLD patients and 18 subjects with histologically normal liver.
Results: In hypoxic hepatocytes, CD36 expression and intracellular lipid content were 
augmented. Noteworthy, CD36 knockdown significantly reduced lipid accumulation, 
and HIF2A gene silencing markedly reverted both hypoxia-induced events in hypoxic 
liver cells. Moreover livers from Vhlf/f-deficient mice showed histologic characteris-
tics of non-alcoholic steatohepatitis (NASH) and increased CD36 mRNA and protein 
amounts, whereas both significantly decreased and NASH features markedly amelio-
rated in Vhlf/fHif2αf/f-deficient mice. In addition, both HIF2α and CD36 were signifi-
cantly overexpressed within the liver of NAFLD patients and, interestingly, a significant 
positive correlation between hepatic transcript levels of CD36 and erythropoietin (EPO), 
a HIF2α -dependent gene target, was observed in NAFLD patients.
Conclusions: This study provides evidence that HIF2α drives lipid accumulation in 
human hepatocytes by upregulating CD36 expression and function, and could con-
tribute to hepatosteatosis setup.
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd
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1  | INTRODUC TION
Overnutrition is a major contributor to the development of non-
alcoholic fatty liver disease (NAFLD) because a high consumption 
of saturated fatty acids, cholesterol and fructose along with a 
low intake of polyunsaturated fatty acids, featuring NAFLD pa-
tients, alters hepatic lipid metabolism homeostasis leading to an 
excessive fat accumulation within the liver which activates in-
flammation, hepatocellular damage and fibrogenesis.1,2 There 
is extensive clinical and experimental evidence indicating that 
chronic intermittent hypoxia, featuring a respiratory disorder 
of growing prevalence worldwide termed obstructive sleep ap-
noea, could contribute to the progression of NAFLD from sim-
ple steatosis, also termed non-alcoholic fatty liver (NAFL) or 
hepatosteatosis, to non-alcoholic steatohepatitis (NASH),3-6 the 
most clinically relevant form of NAFLD with a significant risk to 
progress into cirrhosis and hepatocellular carcinoma,7,8 as well 
as increasing the cardiovascular morbidity and mortality and the 
incidence of extrahepatic cancers.9,10
Hypoxia-inducible factors (HIFs), particularly HIF1α and HIF2α, 
are master regulators of hypoxia-induced cellular adaptive re-
sponses elicited to restore cell metabolism and survival.11 HIFs are 
implicated in numerous physiological and pathological conditions, 
and it has been reported that HIF2α promotes NASH in mice,12,13 
and dysregulates lipid metabolism in HepG2 cells.14 Since lipotoxic-
ity due to free fatty acids (FFAs) overload within hepatocytes plays 
a central role in NAFLD pathophysiology,15 and that this process is 
largely regulated by membrane-bound FFA transporters, it is con-
ceivable that HIFs might contribute to NAFLD pathogenesis by up-
regulating the expression and function of FFA transporters in the 
membrane of hepatocytes.
Among membrane-bound FFA transporters, the fatty acid 
translocase CD36 (CD36) is the best characterized.16 CD36 func-
tions as a high affinity receptor for long-chain FFAs contributing 
under excessive fat supply to lipid accumulation and metabolic 
dysfunction.17 This FFA receptor is involved in several aspects of 
lipid metabolism including fat taste perception, fat intestinal ab-
sorption and FFA utilization by muscle, adipose tissues and liver.18 
Regarding the latter, hepatic CD36 expression is normally weak 
but it increases by a number of different stimuli such as cytokines 
or insulin.18,19 Noteworthy, experimental studies have demon-
strated that CD36 plays a key role in the hepatosteatosis setup 
in rodents 20,21 and, more interestingly, NAFLD patients present 
high hepatic CD36 mRNA levels,22 and this FFA transporter is 
largely overexpressed in the plasma membrane of hepatocytes.23 
While there are evidences that HIF1α upregulates CD36 expres-
sion and function in retinal epithelial cells and macrophages,24,25 
whether HIF2α is able to regulate CD36 gene expression in he-
patocytes still remains to be elucidated.
Therefore, the aim of the present study was to determine 
the impact of HIF2α on CD36 expression and function as well 
as on lipid content in hepatocytes submitted to hypoxic con-
ditions, in livers from genetically-modified mice in which von 
Hippel-Lindau (Vhl) gene is inactivated (Vhlf/f-deficient mice), a 
murine experimental model which displays NAFLD features due 
to an overexpression of HIF1 and HIF2, in livers from mice in 
which both Vhl and Hif2a are simultaneously inactivated (Vhlf/
fHif2αf/f-deficient mice), and in livers from patients with biop-
sy-proven NAFLD.
2  | MATERIAL S AND METHODS
2.1 | Cell culture and treatment
Human hepatoma Huh7 cells and AML12 (alpha mouse liver 12) 
hepatocyte cell line were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA). Huh7 cells were cul-
tured in Dulbecco's modified Eagle's medium (DMEM) containing 
high glucose, penicillin/streptomycin and 10% fetal bovine serum, 
and AML12 hepatocytes were cultured in DMEM:F12 medium 
containing high glucose, penicillin/streptomycin and 10% fetal bo-
vine serum, supplemented with 10 µg/mL insulin, 5.5 µg/mL trans-
ferrin, 5 ng/mL selenium and 40 ng/mL dexamethasone. The cells 
were submitted to normoxic (21% O2) or hypoxic conditions (1% 
O2) in a hypoxic chamber InvivO2 200 (Ruskinn Technology Ltd.) 
for 36 hours.
2.2 | Short hairpin CD36 or HIF2α knockdown
Human scrambled (shControl, shC), CD36 shRNA or HIF2α shRNA 
lentiviral particles (Dharmacon, Madrid, Spain) were used to pro-
duce stable CD36 or HIF2α knockdown in Huh7 cells. Proliferating 
cells were co-incubated with lentiviral transducing particles in 
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culture media containing polybrene (Santa Cruz Biotechnology Inc, 
Heidelberg, Germany) for 24 hours, and then cultured with 2-5 µg/
mL of puromycin (Santa Cruz Biotechnology, Inc). Resistant cells 
were expanded and examined for CD36 or HIF2A mRNA levels 
respectively.
2.3 | Nile Red staining
The cells were fixed with paraformaldehyde 4% for 30 minutes at 
4ºC, and resuspended in Nile Red working solution to 0.4 µL/mL 
(Sigma-Aldrich Inc). The fluorescence was determined using a flow 
cytometer Cytomics FC500 MPLTM (Beckman-Coulter Inc).
2.4 | Animals
All animal experimentation was conducted in accordance with 
Spanish and European legislation and approved by the research 
ethics committee at the Universidad Autónoma de Madrid 
(UAM) (CEI55-1002-A049). Mice used in this study were main-
tained in light/dark (12h light/12 hours dark), temperature (22°C) 
and humidity-controlled rooms, fed with standard chow diet 
(LASQCdiet®Rod14, LASvendi, Germany) ad libitum, and had 
free access to drinking water at the animal facilities of the UAM. 
Vhlfloxed-Ubc-Cre-ERT2 (Vhlf/f-deficient mice), VhlfloxedHIF2αfloxed-
Ubc-Cre-ERT2 (Vhlf/fHif2αf/f-deficient mice) mice and their 
corresponding controls (Vhlfloxed lacking UBC-Cre-ERT2 or 
VhlfloxedHIF2αfloxed lacking UBC-Cre-ERT2) were generated as de-
scribed.26 Male mice at 4-5 months of age were used in this study. 
For gene inactivation, mice were fed ad libitum with Teckland 
CRD TAM400/CreER tamoxifen pellets (Harland-Teklad, Valencia, 
Spain) for 10-15 days, including control mice, and were later re-
turned to standard chow diet for 15 days. After that, mice were 
sacrificed and livers were harvested.
2.5 | Patients
This study included 33 patients with a clinical diagnosis of NAFLD 
(18 NAFL and 15 NASH), and 18 subjects with normal liver (NL) 
who underwent a liver biopsy by a percutaneous route during pro-
grammed cholecystectomy. Characteristics of the study population 
are detailed in Table 1. All NAFLD patients and NL subjects stud-
ied drank less than 20 g/day of alcohol, were not having potentially 
hepatotoxic drugs, had no analytical evidence of iron overload, 
and were seronegative for autoantibodies and for hepatitis B virus, 
hepatitis C virus and human immunodeficiency virus. This study 
was performed in agreement with the Declaration of Helsinki, and 
with local and national laws. The Human Ethics Committee of the 
Hospital Universitario Santa Cristina approved the study procedures 
(PI-688A), and all participants signed an informed written consent 
before inclusion in the study.
2.6 | Gene expression analysis by real-time 
quantitative PCR
Total RNA from cells or liver samples was extracted using TRIzol 
reagent (Vitro, Sevilla, Spain) and was reverse transcribed using a 
TA B L E  1   Characteristics of the study population
Feature NL (n = 18)
NAFL 
(n = 18) NASH (n = 15)
Age (years) 48.2 ± 12.9 54.3 ± 14.9 47.4 ± 11.7
Body mass index 
(kg/m2)
27.1 ± 4.2 29.9 ± 4* 29.4 ± 2.7
Glucose (mg/dL) 91.4 ± 11.1 96.1 ± 9.6 98.6 ± 15.6
Insulin (µU/L) 7.6 ± 6.6 9.6 ± 4.1* 11.5 ± 5.3*
HOMA-IR 1.7 ± 0.9 2.3 ± 1.1* 2.8 ± 1.4*
Triglycerides 
(mg/dL)
110 ± 38.8 135.3 ± 39.8* 138.9 ± 40.4*
HDL-cholesterol 
(mg/dL)
48.3 ± 10.8 49.5 ± 8.9 46.3 ± 8.9
ALT (IU/L) 17.2 ± 5.9 24.6 ± 9.3** 42.8 ± 18.6***
AST (IU/L) 17.3 ± 3.8 20.3 ± 5.1* 27 ± 11.9***























Note: Data are presented as mean ± standard deviation or as number of 
cases (%). Study population: Normal liver (NL) individuals (n = 18), NAFL 
patients (n = 18) and NASH patients (n = 15). HOMA-IR, homeostatic 
model assessment-insulin resistance; HDL, high-density lipoprotein; 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, 
gamma-glutamyltransferase. *P < .05, **P < .01 and ***P < .005, NAFL 
or NASH vs NL.
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reverse transcription system (Promega Inc) in a T100TM Thermal 
Cycler (BioRad Inc, Madrid, Spain) following manufacturer's indica-
tions. Quantitative real-time polymerase chain reaction (qPCR) was 
performed with StepOnePlusTM Real Time PCR System sequence 
detector (Thermo Fisher Scientific, Inc, Madrid, Spain) using the 
SYBR Green method and d(N)6 random hexamer with primers pur-
chased from Metabion (Steinkirchen, Germany). Each sample was 
run in duplicated and normalized to 36B4 (mouse and human sam-
ples) or HPRT (cell samples) gene expression. Fold changes were de-
termined using the ΔΔCt method. Primer sequences are detailed in 
Table 2.
2.7 | Preparation of total protein extracts
Liver biopsy samples were homogenized in 16 volumes (w/v) of 
cold lysis buffer (50 mM Tris-HCl, 1% Triton X-100, 2 mM EGTA, 
10 mM EDTA acid, 100 mM NaF, 1 mM Na4P2O7, 2 mM Na3VO4, 
100 µg/ml phenylmethylsulphonyl fluoride and protease inhibi-
tors). To obtain total cell lysates, at the end of the experiment, 
attached cells were scraped off and incubated for 10 minutes on 
ice with RIPA buffer (50 mM Tris HCl, pH 7.4, 1% Triton X-100, 
0.2% sodium dodecyl sulfate (SDS), 1 mM EDTA, 1 mM PMSF and 
5 µg/ml leupeptin). Protein extracts were stored at −80ºC after 
centrifugation.
2.8 | Extraction of nuclear protein liver extracts
Liver biopsy samples were homogenized in 4 volumes (w/v) of 
cold buffer A (0.3 M Sucrose solution with protease inhibitors). 
Samples were centrifuged and the supernatant containing the 
cytosolic fraction was stored at −80ºC. The pellet containing the 
nuclear fraction was washed for a total of three times with buffer 
A. Samples were incubated in rotation for 1 hour with cold buffer B 
(1% Trion x100, 1% Sodium Deoxycholate, 0.1% SDS, 5 mM EDTA, 
200 nM NaCl, 20 mM Tris HCl pH 8 with protease inhibitors). After 
sonication, cellular debris was removed by centrifugation and the 
supernatant fraction containing the nuclear fraction was stored at 
−80ºC.
2.9 | Western blot analysis
After protein content determination with Bradford reagent, 
50 µg of total protein or100 µg of nuclear protein was boiled 
in Laemmli sample buffer and submitted to 8% SDS-PAGE gels. 
Proteins were transferred to Inmunoblot nitrocellulose mem-
brane (BioRad Inc) and, after blocking with 5% non-fat dry milk, 
incubated overnight with different antibodies as indicated: 
anti-HIF1α (1:1000, 10006421, Cayman Chemical, Hamburg, 
Germany), anti-HIF2α (1:1000, ab199, Abcam, Cambridge, UK) 
and anti-CD36 (1:1000, NB400-144, Novus, Abingdon, UK). 
Immunoreactive bands were visualized using the enhanced 
chemiluminescence (ECL) Western blotting protocol (BioRad 
Inc). The anti-βactin (1:5000, A-5441, Sigma-Aldrich Inc) and the 
anti-lamin B (1:1000, ab65986, Abcam) antibodies were used 
as loading control for total and nuclear protein respectively. 
Densitometric analysis of the bands was performed using Image 
J software (NIH, Bethesda, MD).
2.10 | Histopathology assessment
Paraffin-embedded liver biopsy sections (4 µm thick) 
were stained with haematoxylin/eosin and evaluated by a 















TA B L E  2   Primer sequences for 
RT-qPCR
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single-blinded hepatopathologist. Steatosis was determined 
grading percentage involvement by steatotic hepatocytes as fol-
lows: grade 0, 0%-5%; grade 1, >5%-33%; grade 2, >33%-66%; 
and grade 3, >66%, as described by Kleiner et al.27 In addition, 
this scoring system was used to evaluate the degree of lobular 
inflammation and hepatocellular ballooning. NAFLD activity 
score was calculated for each liver biopsy studied as described 
elsewhere.27 Histologic diagnosis of liver biopsies from NAFLD 
patients was classified into two groups: simple steatosis without 
hepatocellular ballooning nor lobular inflammation, also termed 
NAFL, and NASH. Minimal criteria for NASH included the com-
bined presence of grade 1 steatosis, lobular inflammation and 
hepatocellular ballooning with or without fibrosis. As we want 
to study early stages of NAFLD, only NASH patients with either 
mild fibrosis (F1) or without fibrosis (F0) were studied and in-
cluded in the same group. Representative images were taken 
using an optical microscope Nikon Eclipse E400 (Nikon, Tokyo, 
Japan).
2.11 | Oil Red O staining
Cryoprotected liver biopsy sections (5 µm) were stained with an 
Oil red O (ORO, Sigma-Aldrich Inc) working solution (60% ORO/
isopropanol w:v) and counter-stained with haematoxylin. Red 
staining was quantified from the images taken using an optical 
microscope Nikon Eclipse E400 (Nikon). Image analysis proce-
dures were performed with the FIJI software (NIH, Bethesda, 
MD). Values were obtained in six different lobular areas where 
hepatocytes are the predominant cell type. The average value was 
considered as ORO staining index for each liver biopsy sample, 
and expressed as arbitrary units which reflect the intensity of the 
staining.
2.12 | HIF2α and CD36 immunohistochemistry
Paraffin-embedded liver biopsy sections (4 µm thick) were 
immunostained with a primary rabbit antibody against HIF2α 
(ab199, Abcam) 28 or CD36 (NB400-144, Novus) diluted to 1:50 
and 1:200 respectively, using the DAKO EnVision™+ System 
(DAKO, Glostrup, Denmark) as described by the manufacturer. 
Liver tissue area occupied by nuclear HIF2α or CD36-positive 
cells was quantified from the images taken using an optical 
microscope Nikon Eclipse E400 (Nikon). Image analysis proce-
dures were performed with the FIJI software (NIH). Values were 
obtained in six different lobular areas where hepatocytes are 
the predominant cell type. The average value was considered 
as nuclear HIF2α or CD36 expression index for each liver bi-
opsy sample, and expressed as percentage of positive nuclei or 
arbitrary units respectively, which reflects the intensity of the 
immunostaining.
2.13 | CD36 and N-cadherin immunofluorescence
Paraffin-embedded liver biopsy sections (4 μm thick) were co-incu-
bated with an anti-CD36 antibody (NB400-144, Novus) and anti-N-
cadherin antibody (BP1-48309, Novus), diluted to 1:200 and 1:25 
respectively, following with the appropriated conjugated second-
ary antibodies Alexa Fluor® 568 goat anti-rabbit IgG (A11011, Life 
Technologies) or Alexa Fluor® 488 goat anti-mouse IgG (A11029, 
Life Technologies). The immunofluorescence-mounting medium 
used was Fluoromont G® (BioNova cientifica). Representative im-
ages were taken using a confocal microscope Leica TCS SP5 X (Leica, 
Barcelona, Spain).
2.14 | Statistical analysis
Data from qPCR and western blot experiments are expressed 
as percentage, and presented as mean ± standard error of mean 
(SEM) relative to control condition (100%); data from immunohis-
tochemistry are expressed as percentage or arbitrary units, and 
presented as mean ± SEM; data from flow cytometry experiments 
are expressed as fold increase, and presented as mean ± SEM rela-
tive to control condition (1). Data were compared using one-way 
analysis of variance (ANOVA) followed by Bonferroni test. All sta-
tistical analyses were performed using the GraphPad Prism 6.0 
software (GraphPad Software Inc, San Diego, CA, USA) and the 
IBM SPSS Statistics 24.0 (SPSS Inc, IBM, Armonk, NY) software 
with two-sided tests, with a P-value of < .05 considered as statisti-
cally significant.
3  | RESULTS
3.1 | Hypoxia induces lipid accumulation and 
CD36 expression in both human and murine 
hepatocytes
To explore the molecular mechanisms involved in the regulation of 
CD36 by hypoxia, Huh7 human liver cells were maintained under 
normoxic conditions (Nx, 21%O2) or submitted to hypoxia (Hp, 
1%O2) for 36h. To assure that hypoxia was achieved in Huh7 cell 
cultures, we assessed the expression of HIFα protein subunits by 
western blot. As Figure 1A shows, HIF1α and HIF2α expression was 
markedly induced by hypoxia. Accordingly, PHD3 upregulation, a 
well-recognized HIF responsive gene, was found in hypoxia-exposed 
Huh7 liver cells (Figure 1B).
Next, we investigated whether Huh7 cells submitted to hy-
poxic conditions would increase their intracellular lipid content 
performing Nile Red staining experiments. After flow cytometry 
analysis, we observed a significant increase in the lipid content of 
Huh7 cells submitted to hypoxia, compared to those maintained 
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under normoxic conditions (Figure 1C). Interestingly, a parallel in-
crease in CD36 mRNA and protein levels was found in hypoxic 
Huh7 cells (Figure 1D). Similar findings were observed in mouse 
hepatocytes (AML12 cell line) submitted to hypoxia in which both 
intracellular lipid content and CD36 expression were significantly 
augmented when compared to normoxic cells (Figure 1E-G).
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3.2 | Silencing of CD36 attenuates hypoxia-induced 
lipid accumulation in liver cells
To elucidate whether CD36 is involved in hypoxia-induced lipid ac-
cumulation in hepatic cells, we infected Huh7 cells with scrambled 
(control, shC) or CD36 shRNA (shCD36) lentiviral particles. With 
this approach, we obtained an average of 70% decrease of mRNA 
and protein levels of CD36 (Figure 2A,B). As depicted in Figure 2F, 
silencing of CD36 significantly reduced lipid accumulation in Huh7 
submitted to hypoxia without altering the induction of hypoxia 
markers (Figure 2C,D) and partly blocking hypoxia-induced CD36 
increase (Figure 2E).
These data propose that CD36 might play a major role in the 
onset of hepatosteatosis under hypoxic conditions.
3.3 | HIF2A silencing markedly reduces both lipid 
accumulation and CD36 upregulation in hypoxic 
human hepatocytes
We next wanted to determine whether HIF2α might be linked to 
hypoxia-induced CD36 upregulation. To this end, we infected Huh7 
cells with scrambled (control, shC) or HIF2α shRNA (shHIF2) len-
tiviral particles achieving a 75% decrease in HIF2A mRNA levels 
(Figure 3A). Under hypoxia conditions, it was observed a reduced 
HIF2α protein stabilization (Figure 3B), as well as PHD3 and EPO 
mRNA levels, while the hypoxia-induced increased expression of 
PGK1, a major HIF1α target gene, remained unchanged (Figure 3C). 
Noteworthy, the reduction of HIF2α significantly decreased both 
lipid accumulation and CD36 upregulation observed in Huh7 cells 
submitted to hypoxia for 36 hours (Figure 3D,E). Taken together 
these data suggest that HIF2α is the responsible for the hypoxia-
induced CD36 upregulation and, ultimately, for the increase of lipid 
content in hypoxic hepatocytes.
3.4 | Lack of HIF2α ameliorates NASH 
features and decreases CD36 content in livers from 
Vhlf/f-deficient mice
To investigate the role of HIF2α -CD36 pathways in the hepatic lipid 
homeostasis in vivo, we used adult Vhlfloxed-Ubc-Cre-ERT2 mice (Vhlf/
f-deficient mice) in which Vhl gene inactivation leads to an elevated 
expression of HIFα protein subunits, and VhlfloxedHif2αfloxed-UBC-
Cre-ERT2 mice (Vhlf/fHif2αf/f-deficient mice) in which both Vhl and 
Hif2a are simultaneously inactivated (Figure 4A).
Histological examination of liver biopsies revealed that con-
trol mice displayed a normal histology while Vhlf/f-deficient mice 
exhibited borderline or definite NASH due to the combined 
presence of steatosis, inflammation and hepatocyte ballooning. 
Interestingly, these NASH features were markedly attenuated in 
livers from Vhlf/fHif2αf/f-deficient mice (Figure 4B,C). Accordingly, 
an Oil Red O staining revealed that lipid accumulation observed 
in liver sections from Vhlf/f-deficient mice was higher than in con-
trol animals, and was reverted in livers from Vhlf/fHif2αf/f-deficient 
mice (Figure 4D).
Interestingly, hepatic Cd36 mRNA levels were significantly 
higher in Vhlf/f-deficient mice than in control mice, as well as Epo and 
Pgk1 mRNA levels which are HIF2α and HIF1α-dependent genes re-
spectively. Noteworthy, in Vhlf/fHif2αf/f-deficient mice, hepatic Cd36 
mRNA levels were significantly lower than in Vhlf/f-deficient mice, in 
parallel to Epo mRNA levels, whereas Pgk1 gene expression was not 
repressed but rather it was over-induced (Figure 4E).
Moreover HIF2α protein expression determined by western blot 
(Figure 5A) and by immunostaining (Figure 5B) was elevated in the 
livers of Vhlf/f-deficient mice. As expected, this increase in HIF2α 
content was not observed in mice with both Vhl and Hif2a inacti-
vated (Figure 5A,B). Regarding HIF2α immunostaining, nuclear stain-
ing was lost in livers from Vhlf/fHif2αf/f-deficient mice with respect 
to those from Vhlf/f-deficient mice, suggesting that the nuclear signal 
observed correspond to endogenous HIF2α (Figure 5B). Indeed, we 
also analysed HIF2α protein content in nuclear extracts by west-
ern blot, and we found similar results which indicate that hepatic 
HIF2α translocation into the nucleus was nearly blocked in Vhlf/
fHif2αf/f-deficient mice (Figure S1A).
In parallel, an increase in CD36 protein expression was ob-
served in the livers of Vhlf/f-deficient mice detected by western blot 
(Figure 5A) and by immunostaining (Figure 5C). In these animals, the 
intensification of CD36 immunostaining was also enhanced in the 
plasma membrane of hepatocytes. Indeed, a co-localization between 
CD36 and N-cadherin, a well-characterized hepatocyte plasma mem-
brane marker,29 was observed (Figure S1B). Noteworthy, hepatic 
CD36 expression was also significantly lower in Vhlf/fHif2αf/f-defi-
cient mice than in Vhlf/f-deficient mice (Figure 5A,C).
Taken together, these findings strongly suggest that HIF2α could 
play an important role on hepatic lipid homeostasis by regulating 
F I G U R E  1   Hypoxia induces lipid accumulation and CD36 expression in hepatocytes. Huh7 cells maintained under normoxic (Nx, 21% 
O2), or hypoxic conditions (Hp, 1% O2) in a hypoxia chamber for 36h. A, Representative blots with the indicated antibodies. B, PHD3 mRNA 
levels. C, (left panel) Representative experiment of Nile Red fluorescence intensity. (right panel) Analysis of intracellular lipid content by Nile 
Red staining. D, (left panel) CD36 mRNA. (right panel) Representative blots with the indicated antibodies and densitometric analysis from 
all blots. ***P < .005, Hp vs Nx (n = 4 independent experiments performed by triplicate). AML12 cells maintained under normoxic (Nx, 21% 
O2), or hypoxic conditions (Hp, 1% O2) in a hypoxia chamber for 36 hours. E, Representative blots with the indicated antibodies. F, (left 
panel) Representative experiment of Nile Red fluorescence intensity. (right panel) Analysis of intracellular lipid content by Nile Red staining. 
G, Representative blots with the indicated antibodies and densitometric analysis from all blots. *P < .005 and ***P < .005, Hp vs Nx (n = 3 
independent experiments performed by duplicate)
2560  |     REY Et al.
F I G U R E  2   CD36 knockdown attenuates hypoxia-induced lipid accumulation in human liver cells. Huh7 cells infected with scrambled 
(shC) or CD36 shRNA (shCD36) lentiviral particles maintained under normoxic (Nx, 21% O2), or hypoxic conditions (Hp, 1% O2) in a hypoxia 
chamber for 36h. A, CD36 mRNA in normoxia. B, C, and E, Representative blots with the indicated antibodies and densitometric analysis 
from all blots. D, PHD3 mRNA levels. F. (left panel) Representative experiment of Nile Red fluorescence intensity. (right panel) Analysis 
of intracellular lipid content by Nile Red staining. *P < .005 and ***P < .005, Hp vs Nx; ##P < .01 and ###P < .005, shCD36 vs shC (n = 4 
independent experiments performed by duplicate)
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F I G U R E  3   HIF2α silencing reduces both lipid accumulation and induction of CD36 expression in human liver cells submitted to hypoxic 
conditions. Huh7 cells infected with scrambled (shC) or HIF2α shRNA (shHIF2) lentiviral particles maintained under normoxic (Nx, 21% 
O2), or hypoxic conditions (Hp, 1% O2) in a hypoxia chamber for 36h. A, HIF2A mRNA levels in normoxia. B, Representative blots with 
the indicated antibodies and densitometric analysis from all blots. C, PHD3, EPO and PGK1 mRNA levels. D, (left panel) Representative 
experiment of Nile Red fluorescence intensity. (right panel) Analysis of intracellular lipid content by Nile Red staining. E, CD36 mRNA levels. 
*P < .05 and ***P < .005, Hp vs Nx; ##P < .01 and ###P < .005, shHIF2 vs shC (n = 4 independent experiments performed by duplicate)
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F I G U R E  4   Lack of HIF2α reverts Vhl inactivation-induced NASH. A, Hepatic Vhl and Hif2a mRNA levels. B, Representative 10X images of 
haematoxylin/eosin (H&E) staining. Scale bar 100 µm. C, NAFLD activity score, steatosis grade, lobular inflammation and hepatocellular ballooning 
grade. D, Representative 20X images of Oil Red O (ORO) staining, and its quantification. Scale bar 100 µm. E, Hepatic Epo, Pgk1 and Cd36 
mRNA levels. Experimental groups: Control, Vhlf/f-deficient mice and Vhlf/fHif2αf/f-deficient mice (n = 6-8 animals/group). *P < .05, **P < .01 and 
***P < .005, Vhlf/f or Vhlf/fHif2αf/f-deficient vs Control mice; #P < .05, ##P < .01 and ###P < .005, Vhlf/fHif2αf/f vs Vhlf/f-deficient mice
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F I G U R E  5   HIF2α deficiency attenuates Vhl inactivation-induced hepatic CD36 overexpression. A, Representative blots with the 
indicated antibodies and densitometric analysis from all blots. B, Representative 10X and 40X images of HIF2α immunostaining, and 
quantification of nuclear HIF2α-expressing cells. Scale bar 100 and 50 µm respectively. C, Representative 20× and 40× images of CD36 
immunostaining, and quantification of CD36-expressing cells. Scale bar 100 and 50 µm respectively. Experimental groups: Control, Vhlf/f-
deficient mice and Vhlf/fHif2αf/f-deficient mice (n = 6-8 animals/group). **P < .01 and ***P < .005, Vhlf/f or Vhlf/fHif2αf/f-deficient vs Control 
mice; ###P < .005, Vhlf/fHif2αf/f vs Vhlf/f-deficient mice
2564  |     REY Et al.
F I G U R E  6   Expression of HIF2α and CD36 is increased within the liver of NAFLD patients. A, Representative 10X images of 
haematoxylin/eosin (H&E) staining. Scale bar 100 µm. B, NAFLD activity score. C, Representative 20× and 40× images of HIF2α 
immunostaining, and quantification of nuclear HIF2α-expressing cells. Scale bar 100 and 50 µm respectively. D, Representative 20× and 
60× images of CD36 immunostaining, and quantification of CD36-expressing cells. Scale bar 100 and 50 µm respectively. E, CD36 and EPO 
mRNA levels. F, Correlation in the study population of matched mRNA expression levels. Study population: Normal liver (NL) individuals 
(n = 18), NAFL patients (n = 18) and NASH patients (n = 15). **P < .01 and ***P < .005, NAFL or NASH vs NL
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the expression and function of the fatty acid receptor CD36 in 
hepatocytes.
3.5 | Expression of HIF2α and CD36 is increased 
within the liver of NAFLD patients
Finally, we wanted to explore whether this link between HIF2α 
and CD36 exists in human liver as well. Representative haema-
toxylin/eosin staining liver pictures and the mean of the NAFLD 
activity score from the study patients are shown in Figure 6A,B. 
Furthermore, we estimated the hepatic protein content of nuclear 
HIF2α and total CD36 assessing their expression by immunohisto-
chemistry. A higher expression of HIF2α was observed in NAFLD 
patients, such in NAFL as in NASH cases, than in NL individuals 
(Figure 6C). Interestingly, HIF2α immunostaining was also more in-
tense in the nucleus of hepatocytes in NAFLD patients, which is in 
line with nuclear HIF2 expression upon Vhl inactivation in mouse 
liver shown in Figure 5B. Moreover in agreement with previous re-
sults reported by our group,23 CD36 was weakly expressed in liver 
biopsies from NL subjects, while is markedly expressed at the plasma 
membrane and cytoplasm of numerous hepatocytes in NAFL and 
NASH patients (Figure 6D). Further immunofluorescence staining 
revealed that CD36 co-localized with N-cadherin in NAFLD human 
samples (Figure S1C), which was also found in Vhlf/f-deficient mice 
(Figure S1B). Finally, we measured hepatic mRNA levels of CD36 
and EPO, being the latter one of the best-characterized HIF2α-
dependent gene targets. Therefore, we used EPO mRNA content as 
a surrogate marker of HIF2α activation. We found that both CD36 
and EPO mRNA expression was elevated in NAFLD patients and, 
interestingly, a significant positive correlation between the mRNA 
levels of these genes was observed in the entire study population 
(Figure 6E,F).
4  | DISCUSSION
This study not only demonstrates for the first time that HIF2α 
upregulates CD36 expression and function contributing to hepa-
tosteatosis in hepatocytes, but it also provides evidence suggest-
ing that a HIF2α-induced CD36 upregulation could be operative 
in vivo and play a relevant role in NAFLD pathophysiology in hu-
mans, as we found a significant increase of both HIF2α and CD36 
protein content, and an elevated mRNA levels of CD36 and EPO, 
being the latter a well-known surrogate marker of HIF2α activa-
tion, as well as a marked positive correlation between these genes, 
in the livers of NAFLD patients. It is important to note that al-
though hepatic mRNA levels of both CD36 and EPO were higher 
in NAFL than in NASH patients, the differences between these 
groups were not significant. Likewise, hepatic protein amounts of 
both CD36 and HIF2α were similar in NAFL and NASH patients 
indicating that its hepatic expression remains largely stable during 
histological progression from NAFL to NASH. Taken together, our 
data strongly suggest that the HIF2α/CD36 pathway could have a 
pathogenic role in the phase of hepatosteatosis, but further inves-
tigation is needed for understanding in depth its impact on NASH 
progression.
There is a growing evidence indicating that hypoxia contributes 
to NAFLD development and progression to NASH likely by the ef-
fects that HIFs exert on target genes regulating glucose and lipid 
homeostasis in the adipose tissue, small intestine and liver.30-32 
Regarding the latter, HIF2α-dependent effects in the liver appear 
to be linked to its activation level, thus mild HIF2α activation will 
enhance insulin signalling and fatty acid oxidation whereas potent 
HIF2α activation will lead to liver dysfunction and steatosis.33 In 
our study, 2 weeks after transgene excision, Vhlf/f-deficient mice 
showed mild to moderate NASH features with a median NAFLD ac-
tivity score of 4.5, similar findings to that reported by Qu et al13 In 
particular, these authors observed that livers of mice overexpress-
ing HIFs after 2 weeks of disrupting the Vhl gene in hepatocytes dis-
played NASH features along with a marked increase of Cd36 mRNA 
levels. More interestingly, in agreement with our findings showed 
herein, they also found that the combined inactivation of Vhl and 
Hif2a genes in hepatocytes reverted hepatic steatosis and inflam-
mation observed in Vhlf/f-deficient mice, indicating that HIF2α 
is a direct regulator of lipid homeostasis in the liver, but whether 
HIF2α exerts its steatogenic effect by upregulating genes import-
ant for FFA uptake in hepatocytes, such as CD36, is still unknown. 
Shedding light on this issue, our findings provide a robust exper-
imental evidence demonstrating that HIF2α not only upregulates 
CD36 expression in human liver cells but also its function as FFA 
transporter because we found a marked decrease of hypoxia-in-
duced lipid content and CD36 mRNA levels when we knocked down 
HIF2α in hepatocytes. Further experimental studies, however, are 
needed to prove whether the induction of CD36 by HIF2α occurs 
directly or indirectly, but it is conceivable that HIF2α could activate 
CD36 gene expression in human hepatocytes at the transcriptional 
level as it has been reported at least one putative hypoxia response 
element consensus site at human CD36 gene promoter.24
To the best of our knowledge, this is the first study demonstrat-
ing that hypoxia upregulates CD36 expression and function in he-
patocytes, and that CD36 gene knockdown markedly reduces the 
increased FFA uptake in these hypoxic hepatocytes. In addition, 
another novel finding of this study is the concomitant increase in 
HIF2α and CD36 protein content in the liver of NAFLD patients. In 
particular, noteworthy, such in NAFLD patients as in Vhlf/f-deficient 
mice, the increase in HIF2α expression was markedly observed in 
the nuclei of hepatocytes and that of CD36 was also detected at 
the plasma membrane of hepatocytes. More interestingly, we ob-
served that histological features of NASH significantly ameliorated 
in Vhlf/fHif2αf/f-deficient mice along with a marked decrease of both 
mRNA and protein hepatic CD36 levels, supporting our assumption 
that HIF2α may contribute to NAFLD onset by upregulating CD36 
expression and function in hepatocytes.
The subcellular distribution of CD36 is critical for the regulation 
of its functional activity as FFA transporter facilitating the uptake 
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and influx of FFA to the cells, remaining functionally inactive at in-
tracellular storage pools and active when translocated to the plasma 
membrane.34 In line with our present findings and reinforcing oth-
ers we previously reported,23 Zhao et al 35 have recently confirmed 
that CD36 is largely located in the plasma membrane of hepato-
cytes such in NASH patients as in mice with histological features of 
NASH, providing further evidence indicating the key role of palmi-
toylation in regulating CD36 translocation to the plasma membrane 
of hepatocytes. Protein palmitoylation is mediated by a family of 
palmitoyl acyltransferases (PAT).36 In humans, 23 genes encoding 
PAT have been described so far, whose expression and function 
could be regulated from transcriptional to post-translational level.37 
It is tempting to speculate that HIF2α might induce CD36 expression 
and its translocation to the plasma membrane of human hepato-
cytes by upregulating PAT gene expression, thus increasing CD36 
palmitoylation which facilitates incorporation of CD36 into plasma 
membranes, but this hypothesis still remains to be addressed.
In conclusion, this study provides novel evidence indicating that 
HIF2α upregulates CD36 expression and function in hepatocytes, and 
could contribute to the onset of hepatosteatosis. Unveiling the mo-
lecular mechanisms underlying the HIF2α-dependent CD36 upregu-
lation in human hepatocytes may have notable implications for the 
development of new pharmacological therapies inhibiting the HIF2α/
CD36 pathway trying to attenuate the excessive fat accumulation 
within the liver and its detrimental effects on the outcome of NAFLD.
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